{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:52:14Z","timestamp":1787759534539,"version":"build-2784847793"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,3]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The goal of this study was to estimate the relative efficacy and safety of different biological agents (infliximab, canakinumab, baricitinib, anakinra, adalimumab, tofacitinib, tocilizumab, and rilonacept) compared with placebo for systemic juvenile idiopathic arthritis (JIA) patients, through a network meta-analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Pubmed, Embase, and Cochrane Library were searched from database inception to July 2023 for randomized controlled trials comparing different biological agents (infliximab, canakinumab, baricitinib, anakinra, adalimumab, tofacitinib, tocilizumab, and rilonacept) or placebo directly or indirectly in JIA. Bayesian network meta-analyses were conducted. Data was extracted and analyzed by R with gemtc package. The treatment options were ranked using the surface under the cumulative ranking curve (SUCRA) value.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We identified 10 randomized controlled trials and analyzed 898 participants. Canakinumab (odds ratio 55.0, 95% credible intervals 2.4\u201367.0) was more effective than the placebo, and the difference was statistically significant. However, there was no statistical significance between other drugs versus placebo in terms of the modified ACRpedi30 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&gt;\u2005.05). The SUCRA shows that canakinumab ranked first (SUCRA, 86.9%), anakinra ranked second (SUCRA, 77.7%), adalimumab ranked third (SUCRA, 61.9%), and placebo ranked the last (SUCRA, 6.3%). Nevertheless, there were no notable discrepancies in the occurrence of adverse events, hepatic-related adverse events, infectious adverse event, serious adverse events, and serious infection following treatment with canakinumab, anakinra, tocilizumab, rilonacept, or the placebo. Based on the clustergram of modified ACRpedi30 and adverse events, canakinumab is suggested for JIA according to the surface under SUCRAs considering the symptom and adverse events simultaneously.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Among patients with JIA, canakinumab exhibited the highest likelihood of being the optimal treatment for achieving the modified ACRpedi30 response rate, and neither of the tested biological agents carried a significant risk of serious adverse events.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000038002","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T18:04:30Z","timestamp":1714759470000},"page":"e38002","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Comparative efficacy and safety of different drugs in patients with systemic juvenile idiopathic arthritis: A systematic review and network meta-analysis"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6322-612X","authenticated-orcid":false,"given":"Baoquan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Huaihe Hospital of Henan University, Kaifeng, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Joint Logistics Support Force 989 Hospital, Luoyang, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenbiao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Huaihe Hospital of Henan University, Kaifeng, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ping","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Huaihe Hospital of Henan University, Kaifeng, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Zhou","sequence":"additional","affiliation":[{"name":"Zhengzhou Yihe Hospital affiliated to Henan University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Laboratory, Henan Cancer Hospital, Zhengzhou, Henan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhou","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Huaihe Hospital of Henan University, Kaifeng, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.berh.2018.02.002","article-title":"Systemic juvenile idiopathic arthritis: new insights into pathogenesis and cytokine directed therapies.","volume":"31","author":"Pardeo","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.autrev.2017.10.007","article-title":"HLA-DRB1 alleles and juvenile idiopathic arthritis: diagnostic clues emerging from a meta-analysis.","volume":"16","author":"De Silvestri","year":"2017","journal-title":"Autoimmun Rev"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40272-013-0038-0","article-title":"Glucocorticoids in the management of systemic juvenile idiopathic arthritis.","volume":"15","author":"Vannucci","year":"2013","journal-title":"Paediatr Drugs"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s12519-022-00530-8","article-title":"Research progress in drug therapy of juvenile idiopathic arthritis.","volume":"18","author":"Zhao","year":"2022","journal-title":"World J Pediatr"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40272-021-00436-4","article-title":"Prescribing patterns and impact of factors associated with time to initial biologic therapy among children with non-systemic juvenile idiopathic arthritis.","volume":"23","author":"Yue","year":"2021","journal-title":"Paediatr Drugs"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/rheumatology\/kev382","article-title":"Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials.","volume":"55","author":"Tarp","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/art.42656","article-title":"Recombinant interleukin-1 receptor antagonist is an effective first-line treatment strategy in new-onset systemic juvenile idiopathic arthritis, irrespective of HLA-DRB1 background and IL1RN variants.","volume":"76","author":"Erkens","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1093\/rheumatology\/keab047","article-title":"Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.","volume":"60","author":"Ruperto","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R9-20250504","first-page":"622","article-title":"Long-term safety of canakinumab in systemic JIA.","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N Engl J Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00011-012-0455-5","article-title":"Associations between TNFAIP3 gene polymorphisms and rheumatoid arthritis: a meta-analysis.","volume":"61","author":"Lee","year":"2012","journal-title":"Inflamm Res"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/art.38042","article-title":"Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis.","volume":"65","author":"Lovell","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(23)00921-2","article-title":"Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.","volume":"402","author":"Ramanan","year":"2023","journal-title":"Lancet"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","article-title":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.","volume":"70","author":"Tynj\u00e4l\u00e4","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"R230","DOI":"10.1186\/ar4072","article-title":"Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement.","volume":"14","author":"Horneff","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/acr.22657","article-title":"A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis.","volume":"67","author":"Burgos-Vargas","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"239","DOI":"10.5414\/CP203791","article-title":"Comparison of the efficacy and safety of biological agents in patients with systemic juvenile idiopathic arthritis: a Bayesian network meta-analysis of randomized controlled trials.","volume":"59","author":"Song","year":"2021","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1136\/annrheumdis-2012-201991","article-title":"Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons.","volume":"72","author":"Otten","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/14712598.2023.2282133","article-title":"The safety of canakinumab in systemic juvenile idiopathic arthritis and autoinflammatory diseases in pediatric patients: a multicenter study.","volume":"23","author":"Co\u015fkuner","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41584-023-01042-z","article-title":"Treatment of systemic juvenile idiopathic arthritis.","volume":"19","author":"Hinze","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/mr\/roab119","article-title":"Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis-associated refractory macrophage activation syndrome.","volume":"32","author":"Wu","year":"2022","journal-title":"Mod Rheumatol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/rheumatology\/keab619","article-title":"Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort.","volume":"61","author":"De Matteis","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.rdc.2023.06.007","article-title":"Molecular pathways in the pathogenesis of systemic juvenile idiopathic arthritis.","volume":"49","author":"Schulert","year":"2023","journal-title":"Rheum Dis Clin North Am"},{"key":"R31-20250504","first-page":"390","article-title":"Canadian rheumatology association recommendations for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis.","volume":"50","author":"Berard","year":"2023","journal-title":"J Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:06:18Z","timestamp":1746320778000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":29,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000038002","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]}}}